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Abstract
Background: Merozoite surface protein 142 (MSP142) is a leading blood stage malaria vaccine candidate. In order to induce
immune responses that cover the major antigenic polymorphisms, FVO and 3D7 recombinant proteins of MSP142 were
mixed (MSP142-C1). To improve the level of antibody response, MSP142-C1 was formulated with Alhydrogel plus the novel
adjuvant CPG 7909.
Methods: A Phase 1 clinical trial was conducted in healthy malaria-naı ¨ve adults at the Center for Immunization Research in
Washington, D.C., to evaluate the safety and immunogenicity of MSP142-C1/Alhydrogel +/2 CPG 7909. Sixty volunteers
were enrolled in dose escalating cohorts and randomized to receive three vaccinations of either 40 or 160 mg protein
adsorbed to Alhydrogel +/2 560 mg CPG 7909 at 0, 1 and 2 months.
Results: Vaccinations were well tolerated, with only one related adverse event graded as severe (Grade 3 injection site
erythema) and all other vaccine related adverse events graded as either mild or moderate. Local adverse events were more
frequent and severe in the groups receiving CPG. The addition of CPG enhanced anti-MSP142 antibody responses following
vaccination by up to 49-fold two weeks after second immunization and 8-fold two weeks after the third immunization when
compared to MSP142-C1/Alhydrogel alone (p,0.0001). After the third immunization, functionality of the antibody was
tested by an in vitro growth inhibition assay. Inhibition was a function of antibody titer, with an average of 3% (range 22t o
10%) in the non CPG groups versus 14% (3 to 32%) in the CPG groups.
Conclusion/Significance: The favorable safety profile and high antibody responses induced with MSP142-C1/Alhydrogel +
CPG 7909 are encouraging. MSP142-C1/Alhydrogel is being combined with other blood stage antigens and will be taken
forward in a formulation adjuvanted with CPG 7909.
Trial Registration: ClinicalTrials.gov Identifier: NCT00320658
Citation: Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, et al. (2010) Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP142-C1/Alhydrogel with
and without CPG 7909 in Malaria Naı ¨ve Adults. PLoS ONE 5(1): e8787. doi:10.1371/journal.pone.0008787
Editor: Vasee Moorthy, World Health Organisation, Switzerland
Received October 8, 2009; Accepted December 2, 2009; Published January 22, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by the Intramural program of the National Institutes of Health, National Institute of Allergy and Infectious Disease. Supportf o r
this project was provided in part by the PATH Malaria Vaccine Initiative (MVI), which also supports the Growth Inhibition Assay (GIA) Reference Center, and by the
United States Agency for International Development (USAID) Malaria Vaccine Development Program through a cooperative agreement between USAID and MVI.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Laura Martin is currently an employee of Novartis Vaccines Institute. However Novartis played no role in this study, either as a funder
or collaborator, and Dr. Martin’s work on this project was completed before her affiliation with Novartis began. Neither this nor any other author’s affiliation alters
the adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: ellisru@niaid.nih.gov
¤a Current address: Novartis Vaccines Institute for Global Health, Siena, Italy
¤b Current address: The Rayne Institute, Division of Imaging Sciences, School of Medicine, King’s College London, United Kingdom
¤c Current address: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Maryland, United
States of America
Introduction
The P. falciparum parasite is responsible for at least 300 million
acute cases of malaria each year, with an estimated 1 million
deaths, most in children in Africa [1]. Morbidity and mortality
caused by malaria also have significant direct and indirect effects
on the economic development of malaria-endemic countries [2].
Growing drug resistance of the parasite, widespread resistance of
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human travel make the sustainability of the recent advances
against malaria uncertain, and a vaccine that reduced mortality
and morbidity secondary to P. falciparum would be a valuable
resource in the fight against this disease. One vaccine, RTS,S, is
currently entering Phase 3 clinical trials; however this vaccine has
only shown 30–65% efficacy in previous field studies [3], and a
vaccine with higher levels of protection is still sought.
Over time, people living in malaria-endemic areas develop
immunity to clinical disease caused by P. falciparum, and IgG from
immune adults has been shown to reduce parasite density and
clinical symptoms when administered to children with clinical
malaria [4,5]. Thus, proteins expressed during the blood stage of
the parasite life cycle have been proposed as good candidates for
inclusion in a vaccine. Rather than preventing infections, the
purpose of a blood-stage vaccine is to reduce or prevent severe
illness and complications of the disease such as cerebral malaria,
anemia, and renal failure. Two leading vaccine candidates are
apical membrane antigen 1 (AMA1) and merozoite surface protein
1 (MSP1), both of which are expressed on the merozoite surface
and are thought to be involved in invasion of red blood cells.
MSP142 is a 42 kDa fragment of MSP1 which undergoes
secondary processing and cleavage into MSP133 and MSP119
[6]. Vaccination with MSP142 formulated in water-in-oil adjuvants
induced protection in Aotus nancymai monkeys experimentally
infected with P. falciparum, and protection from high parasitemia
was correlated with antibody levels and in vitro growth inhibition
[7]. Another study in Aotus found protection to be correlated with
antibody responses, and to be adjuvant dependent, with higher
levels of protection seen in the groups receiving antigen with
complete/incomplete Freund’s Adjuvant or ISA-720 compared to
that receiving antigen with AS02A [8]. A Phase 2b study of the
3D7 allelic form of MSP142 adjuvanted with AS02 in children in
Kenya showed that the vaccine was not protective despite high
antibody levels [9].
A previous study found the FVO and 3D7 allelic proteins of
MSP142 to be safe but not sufficiently immunogenic when
adjuvanted with Alhydrogel [10]. The novel adjuvant CPG 7909
has been found to induce high antibody responses and in vitro
growth inhibition of up to 96% when added to the candidate
blood stage vaccine AMA1-C1/Alhydrogel [11,12]. In the study
presented here a vaccine containing the FVO and 3D7 proteins of
MSP142, MSP142-Combination 1 (C1), adjuvanted on Alhydrogel
with and without CPG 7909, was evaluated in malaria naı ¨ve
adults.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Design
This randomized, double-blind, Phase I clinical trial was
designed to evaluate the safety, reactogenicity and immunogenicity
of the MSP142-C1 malaria vaccine formulated on AlhydrogelH,
with or without CPG 7909, in malaria-naı ¨ve adults. This study was
performed under an investigational new-drug application (BB-
IND-12418) reviewed by the U.S. Food and Drug Administration
(FDA). The protocol was approved by the Western Institutional
Review Board (Johns Hopkins Bloomberg School of Public
Health) and the National Institute of Allergy and Infectious
Diseases Institutional Review Board. The study was conducted
at the Center for Immunization Research, Johns Hopkins
Bloomberg School of Public Health. (ClinicalTrials.gov Identifier:
NCT00320658)
Thirty volunteers each were enrolled into low and high dose
cohorts, 40 mg MSP142/AlhydrogelH and 160 mg MSP142/Alhy-
drogelH, for a total of 60 volunteers. Within each cohort volunteers
were randomized 1:1 to receive the vaccine with or without
560 mg CPG 7909. Enrollment was staggered for safety purposes
such that 10 volunteers from each cohort (5 receiving the vaccine
without CPG 7909 and 5 receiving the vaccine with CPG 7909)
were enrolled, vaccinated, and followed for one week before
vaccination of the remaining volunteers in the cohort. Volunteers
in the high dose cohort were not vaccinated until two weeks after
volunteers in the low dose cohort had received their third
vaccination. Volunteers were vaccinated on study days 0, 28,
and 56 with a 0.5 mL intramuscular injection given in alternate
arms. A window of plus or minus one week was allowed for
vaccines 2 and 3. Throughout the paper, study day refers to the
nominal study day.
Participants
Healthy male and non-pregnant female volunteers, ages 18 –
50, were recruited from the metropolitan Washington DC area.
Written informed consent was obtained from volunteers in
accordance with the Code of Federal Regulations Title 21, Part
50. Comprehension was confirmed using a questionnaire prior to
enrollment. Volunteers were excluded if they had any of the
following: evidence of clinically significant disease by examination,
medical history, or clinical laboratory studies; were pregnant or
breast feeding; had serological evidence of HIV, chronic hepatitis
B, or hepatitis C infection; history of surgical splenectomy; receipt
of blood products in the last 6 months; current medication with
corticosteroids or immunosuppressive drugs; history of severe
allergic reaction or anaphylaxis; participation in another investi-
gational vaccine or drug trial within 30 days of enrollment;
immunization with a live vaccine in the previous 4 weeks; prior
malaria infection, previous receipt of a malaria vaccine, travel to a
malaria-endemic country during the past 12 months, or planned
travel to a malaria-endemic country during the course of the study;
and receipt of chloroquine or other aminoquinolines within 12
weeks of study entry. Female volunteers were required to have a
negative urine pregnancy test at least three days prior to
vaccination and on the day of vaccination and to agree to use
contraception or abstain from sexual intercourse for the duration
of the study.
Interventions
The MSP142-C1 vaccine contains an equal mixture of two
highly-purified, recombinant malaria proteins that correspond to
the external domain of MSP142 of the P. falciparum FVO and 3D7
strains. The recombinant proteins were each expressed in E. coli
and purified by a combination of metal affinity chromatography,
protein refolding and subsequent anion-exchange and size-
exclusion chromatography as previously described [10]. Both
protein drug substances were manufactured under current Good
Manufacturing Practices (cGMP) at the Walter Reed Army
Institute of Research, Pilot Bioproduction Facility (Silver Spring,
MD). Equal weight amounts of the MSP142-FVO and MSP142-
3D7 drug substances were mixed together and bound to
aluminum hydroxide (AlhydrogelH, Brenntag Biosector A/S,
Denmark). This formulation was performed under cGMP by the
Pharmaceutical Development Section, Pharmacy Department,
Clinical Center, National Institutes of Health (Bethesda, MD). The
vaccine was supplied in single dose vials as a cloudy liquid
containing MSP142-C1 adsorbed to AlhydrogelH, in sterile saline
MSP142-C1/Alhydrogel6CPG 7909
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tives, for intramuscular (IM) injection. Two lots of the MSP142-
C1/AlhydrogelH vaccine were supplied to the clinical trial site,
containing 40 or 160 mg of MSP142-C1 and 404 mg of aluminum
per 0.5 mL dose in 0.7 mL vials. Each vaccine lot underwent
comprehensive quality control analysis to ensure that the purity,
identity, and integrity of the product met specifications. Storage of
the vaccine lots at the clinical site was confirmed to be between
2–8uC by a continuous temperature monitoring system (Rees
Scientific, Trenton, NJ). The potency and stability of the vaccine
lots were confirmed by evaluation of their immunogenicity in mice
conducted every six months throughout the course of the trial.
CPG 7909 (Coley Pharmaceutical Group, Wellesley, MA) is a
synthetic oligodeoxynucleotide and toll-like receptor 9 agonist that
has been used as an adjuvant for vaccines targeting infectious
diseasesandcancer[13,14].CPG7909wasmanufacturedaccording
to cGMP standards and was supplied in sterile vials at 10 mg/mL in
hypertonic phosphate buffered saline. CPG was added to MSP142-
C1/Alhydrogelatthepointofinjectionshortlybeforevaccination,as
previously described [11], to give a dose of 560 mg.
Randomization and Blinding
Randomization was performed by the study pharmacist, who
prepared the vaccines and kept the study code. The delivery
volumes of the vaccines with and without CPG 7909 were slightly
different (0.55 and 0.50 mL respectively), so opaque tape was used
to mask the contents and maintain blinding by the person
administering vaccines. The study was partially unblinded to assess
outcomes after the third vaccinations; however, all clinical and
immunological assessments were conducted by investigators who
remained blinded until completion of the study.
Outcomes
(i) Safety. The primary objective of the trial was to assess the
safety of the MSP142-C1/AlhydrogelH vaccine with and without
CPG 7909. Following each vaccination, volunteers were observed
for 60 minutes and then returned to the clinic on days 1, 3, 7, and
14 following vaccination for evaluation of local and systemic
reactogenicity. Local reactogenicity was defined as erythema,
swelling, induration, and pain at the injection site. Solicited
systemic adverse events included fever (.37.5uC), headache,
nausea, malaise, myalgia, arthralgia, and urticaria. A complete
blood count with differential and platelet count was tested at each
vaccination and on day 3, 7, and 14 following each vaccination.
Serum alanine aminotransferase (ALT) and creatinine were tested
at each vaccination and on days 3 and 14 following vaccination.
Markers for autoimmunity (anti-double stranded DNA (dsDNA),
anti-nuclear antibody (ANA), complement levels, and rheumatoid
factor) were tested at study Day 0; anti-ds DNA was repeated on
each vaccination day, 7 days after each vaccination, and 1 month
and 6 months after the last vaccination. Urine for blood and
protein were also tested as markers of autoimmunity on the day of
and 14 days after each vaccination. Volunteers were given a digital
thermometer, injection site reaction measurement tool, and
symptom diary card to record their daily temperature, injection
site reactions, and solicited adverse events for 14 days following
each vaccination. All adverse events were graded for severity: mild
(easily tolerated), moderate (interferes with daily activity or
required remedial therapy), or severe (prevents daily activity).
Injection site erythema, swelling, and induration were graded for
severity as follows: mild (.0t o#20 mm), moderate (.20 mm to
#50 mm), severe (.50 mm). The association of the adverse event
with receipt of study vaccine was determined to be definite,
probable, possible, unlikely, or unrelated.
(ii) Immunological assays. Measurements of anti-MSP142
antibody levels were done on serum collected from participants
on study Days 0, 14, 28, 42, 56, 70, 84, 140, and 238. The
standardized methodology for performing the ELISA has been
described previously [15] and OD-based ELISA units were
converted to mg/mL as described previously [16].
The ability of induced anti-MSP142 antibodies to inhibit growth
of P. falciparum FVO and 3D7 parasites was assessed by a
standardized growth inhibition assay (GIA) [17] using IgGs
purified from study Days 0 and 70 sera. Briefly, each test IgG
(10 mg/mL in a final test well) was incubated with synchronized
P. falciparum parasites for ,40 h and relative parasitemia levels
were quantified by biochemical determination of parasite lactate
dehydrogenase.
Statistical Analysis
To compare the frequency of adverse events in the low versus
high dose groups and non-CPG versus CPG groups, logistic
regressions were performed for local and solicited events and for
specific events for which 5 or more subjects had an occurrence.
Exact logistic regression was used if no maximum likelihood
estimate existed. Severity of local and solicited adverse events was
compared using cumulative logit models with main effects for dose
group and CPG, with each participant scored for maximum
severity events as follows: severity=0 (no AE observed), severi-
ty=1 (mild), severity=2 (moderate) and severity=3 (severe). All
subjects receiving any vaccinations were included in the analysis.
No corrections were made for multiple analyses.
All data available for each time point for each subject were used
for the immunological analysis, but for the graphical representa-
tion of antibody levels over time only subjects who did not miss
any antibody measurements were included. Since there was a high
level of concordance between the anti-MSP142-FVO and -3D7
responses (data not shown), the arithmetic average of the response
to both alleles was used as the response for each subject at each
time point. Exact stratified Wilcoxon rank sum tests were used to
calculate two-sided p-values for the effect on antibody responses of
adding CPG, and to compare the dose groups. Tests were
performed at both Day 42 and Day 70 (two weeks after the second
and third vaccinations respectively), and at Day 236 (end of study).
Fold-increases and confidence intervals were estimated using the
Hodge-Lehmann method [18]. The correlation between antibody
level and growth-inhibitory activity was tested by a Spearman rank
test. For growth-inhibitory activity, the effect of adding CPG was
tested by exact stratified Wilcoxon rank sum tests using Day 70
data. Comparison of GIA data between Day 0 and Day 70 was
performed by the Wilcoxon signed rank test for each group.
Calculations were done using R Version 2.9.1, SAS Version 9.1 or
StatXact Procs Version 8.0 and p,0.05 was considered to be
significant.
A group size of 15 participants gave a power per group of 0.8
for detecting serious or medically significant adverse events that
occurred with a frequency of 0.1 per participant. A group size of
30 participants (in the non-CPG and CPG groups combined) gave
a power of 0.8 for detecting a 2.4 fold difference in antibody
responses between the groups, assuming a coefficient of variation
in antibody responses of 1.7 and a significance level of 0.05.
Results
Participant Flow (Figure 1)
Sixty healthy adult volunteers (25 female and 35 male) were
enrolled in the study. The mean age of volunteers was 30.5 years
(range 18 – 50). Thirty volunteers were randomized 1:1 to receive
MSP142-C1/Alhydrogel6CPG 7909
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AlhydrogelH with CPG 7909 (Group B). An additional thirty
volunteers were randomized 1:1 to receive 160 mg MSP142/
AlhydrogelH (Group C) or 160 mg MSP142/AlhydrogelH with
CPG (Group D). Vaccinations began in March, 2006 and all
follow up was complete by April, 2007. Fifty-one volunteers
received all three vaccinations as scheduled. Five volunteers
received only one vaccination and four volunteers received only
two vaccinations; one volunteer was withdrawn after third
vaccination. Of the five volunteers who received only one
vaccination, one volunteer in Group A withdrew consent following
the first vaccination, one volunteer in Group B was lost to follow-
up prior to second vaccination, and three volunteers were
medically ineligible to receive second vaccination due to an
elevated ANA on day 0 prior to first vaccination (one volunteer
each in Groups C and D; blood was drawn prior to vaccination
but results were not available until after enrollment) or due to
receipt of steroids prior to second vaccination (one volunteer in
Group D). Of the four volunteers who did not receive a third
vaccination, three did not receive a vaccination because they were
unavailable for vaccination within the protocol-defined window
(one volunteer each in Groups A, C, and D). The fourth volunteer
did not receive a third vaccination due to receipt of steroids prior
to third vaccination (Group C). One volunteer in Group D was
withdrawn after third vaccination due to incarceration. Eight
volunteers completed all vaccinations but missed one or more
study visits and were missing data points for the graphical
representation of the longitudinal ELISA antibody levels (1 in
Group A, 2 in Group B, 2 in Group C, and 3 in Group D).
Safety and Reactogenicity
No serious adverse events occurred during the study and no
volunteers were withdrawn due to adverse events. Local
reactogenicity, solicited adverse events and selected laboratory
results are shown in Tables 1 and 2. All local adverse events were
mild or moderate with the exception of severe erythema in one
volunteer in Group D (high dose with CPG). Injection site pain
was the most frequent injection site reaction and did not increase
in frequency or severity with subsequent vaccinations. The odds of
having any local adverse event were significantly greater in the
CPG than in the non-CPG groups (p=0.024) but there was no
significant difference between the high and low dose groups
(p=0.65). The odds of having a more severe local adverse event
was greater in the high dose than in the low dose groups (odds
ratio (OR)=6.8, 95% CI 1.7, 27.8, p=0.008), and in the CPG
groups compared to the non-CPG groups (OR=23.6, 95% CI
Figure 1. Flow chart of vaccinations and volunteer participation.
doi:10.1371/journal.pone.0008787.g001
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or moderate and headache was the most frequent systemic adverse
event overall. Solicited adverse events were not significantly more
frequent (p=0.30) nor more severe (OR=1.6, 95% CI 0.6, 4.4,
p=0.4) in the high dose compared to the low dose groups.
Similarly there was no significant difference between the CPG
and the non-CPG groups in either the frequency (p=0.30) or the
severity (OR=2.4, 95% CI 0.8, 7.1, p=0.1) of solicited adverse
events. Of the specific adverse events that occurred frequently
enough to be included in the analysis, injection site swelling and
malaise were more frequent in the CPG groups (p=0.037 and
0.050 respectively) compared to the non-CPG groups. Upper
respiratory infection (URI) was more frequent in the high dose
groups (p=0.014), but this is likely to be a statistical artifact as
URI would not be expected to be related to vaccination. As
expected, transient neutropenia was more frequent in the CPG
groups (p=0.014), as described below. No rashes occurred that
were judged to be related to vaccination.
Transient neutropenia developed in 9 volunteers receiving the
vaccine with CPG 7909: 2 individuals had moderate neutropenia
(moderate neutropenia was defined as absolute neutrophil count
between 500 and 999 cells/mm
3; the lowest levels detected in the
two volunteers were 626 and 961) and the others were mild
(between 1000 and 1499 cells/mm
3). Some volunteers had
neutropenia after more than 1 vaccination but neutropenia did
not become more severe with successive vaccinations. Neutropenia
was also observed in one volunteer that received the vaccine
without CPG. Neutropenia resolved by Day 7 post-vaccination for
all volunteers. No clinical events were associated with the
neutropenia. One volunteer in Group C developed a grade 1
leukocytosis after second vaccination and two volunteers in Group
D developed a grade one leukocytosis after third vaccination; all
resolved within 15 days. One volunteer in Group D developed a
grade 1 leukocytosis 20 days after first vaccination; this was
deemed remotely related to vaccine. Seven volunteers experienced
mild elevation in serum alanine transaminase (ALT): 2 received
the low dose vaccine with CPG, 1 received the low dose vaccine
without CPG, 1 received the high dose vaccine with CPG, and 3
received the high dose vaccine without CPG. Four volunteers
experienced elevation within three days of vaccination which
lasted 4 to 12 days and was considered possibly related to
vaccination; one volunteer experienced mild ALT elevation 13
days post-vaccination lasting 9 days and judged possibly related to
vaccine; one volunteer experienced ALT elevation 28 and 115
days post-vaccination deemed remotely related to vaccination; and
one volunteer experienced ALT elevation 20 days post-vaccination
1 that was deemed remotely related to vaccine. Two volunteers
had elevated ANA (.1:80) at enrollment and were not
revaccinated as per protocol; 28 volunteers had low ANAs (1:40)
at enrollment and were continued in the study without the
subsequent occurrence of events that posed risks to safety. No
positive anti-dsDNA results occurred and no volunteer had a
clinical event related to autoimmunity.
Immune Responses
Geometric mean antibody responses after second and third
immunizations are shown in Figure 2. The highest responses
were in the groups that received 40 and 160 mg MSP142/
Alhydrogel with CPG at Day 42 (2 weeks after second
vaccination), with geometric mean IgG concentrations of 118
and 121 mg/mL, respectively. The addition of CPG significantly
enhanced antibody responses in both the 40 and 160 mg dose
Table 1. Local adverse events.
Vaccination 1 Vaccination 2 Vaccination 3
Total Mild Moderate Severe Total Mild Moderate Severe Total Mild Moderate Severe
40 mg MSP142-C1/AlhydrogelH
Pain 9/15 9 0 0 10/14 10 0 0 3/13 3 0 0
Erythema 1/15 1 0 0 1/14 1 0 0 3/13 3 0 0
Swelling 0/15 0 0 0 0/14 0 0 0 1/13 1 0 0
Induration 0/15 0 0 0 0/14 0 0 0 0/13 0 0 0
40 mg MSP142-C1/AlhydrogelH+CPG 7909
Pain 11/15 11 0 0 10/14 9 1 0 9/14 9 0 0
Erythema 1/15 1 0 0 2/14 2 0 0 3/14 3 0 0
Swelling 1/15 1 0 0 0/14 0 0 0 2/14 2 0 0
Induration 1/15 1 0 0 0/14 0 0 0 0/14 0 0 0
160 mg MSP142-C1/AlhydrogelH
Pain 10/15 10 0 0 9/14 8 1 0 5/12 5 0 0
Erythema 1/15 1 0 0 1/14 1 0 0 2/12 2 0 0
Swelling 0/15 0 0 0 1/14 1 0 0 1/12 1 0 0
Induration 0/15 0 0 0 0/14 0 0 2/12 2 0 0
160 mg MSP142-C1/AlhydrogelH+CPG 7909
Pain 14/15 11 3 0 11/13 7 4 0 9/12 8 1 0
Erythema 0/15 0 0 0 2/13 2 0 0 1/12 0 0 1
Swelling 5/15 2 3 0 3/13 2 1 0 1/12 1 0 0
Induration 0/15 0 0 0 1/13 1 0 0 1/12 1 0 0
doi:10.1371/journal.pone.0008787.t001
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Solicited AE Vaccination 1 Vaccination 2 Vaccination 3
Total Mild Moderate Severe Total Mild Moderate Severe Total Mild Moderate Severe
40 mg MSP142-C1/AlhydrogelH
Fever 0/15 0 0 0 0/14 0 0 0 0/13 0 0 0
Headache 4/15 4 0 0 1/14 1 0 0 3/13 3 0 0
Nausea 1/15 1 0 0 1/14 1 0 0 1/13 1 0 0
Malaise 3/15 3 0 0 0/14 0 0 0 0/13 0 0 0
Myalgia 1/15 1 0 0 0/14 0 0 0 0/13 0 0 0
Arthralgia 1/15 1 0 0 0/14 0 0 0 0/13 0 0 0
Leukopenia 2/15 2 0 0 2/14 2 0 0 0/13 0 0 0
Neutropenia 1/15 1 0 0 1/14 1 0 0 1/13 1 0 0
Anemia 0/15 0 0 0 0/14 0 0 0 0/13 0 0 0
Thrombocytopenia 0/15 0 0 0 0/14 0 0 0 0/13 0 0 0
Elevated ALT 0/15 0 0 0 0/14 0 0 0 1/13 1 0 0
40 mg MSP142-C1/AlhydrogelH+CPG 7909
Fever 1/15 1 0 0 2/14 2 0 0 1/14 1 0 0
Headache 6/15 5 1 0 7/14 6 1 0 3/14 3 0 0
Nausea 1/15 1 0 0 0/14 0 0 0 1/14 1 0 0
Malaise 3/15 2 1 0 2/14 2 0 0 1/14 1 0 0
Myalgia 3/15 3 0 0 2/14 2 0 0 1/14 1 0 0
Arthralgia 3/15 3 0 0 1/14 1 0 0 3/14 2 1 0
Leukopenia 2/15 2 0 0 1/14 1 0 0 1/14 1 0 0
Neutropenia 3/15 1 2 0 5/14 4 1 0 3/14 2 1 0
Anemia 0/15 0 0 0 0/14 0 0 0 0/14 0 0 0
Thrombocytopenia 0/15 0 0 0 0/14 0 0 0 0/14 0 0 0
Elevated ALT 0/15 0 0 0 2/14 2 0 0 0/14 0 0 0
160 mg MSP142-C1/AlhydrogelH
Fever 0/15 0 0 0 1/14 0 1 0 0/12 0 0 0
Headache 3/15 3 0 0 4/14 4 0 0 1/12 1 0 0
Nausea 2/15 2 0 0 1/14 1 0 0 0/12 0 0 0
Malaise 2/15 2 0 0 2/14 2 0 0 0/12 0 0 0
Myalgia 1/15 1 0 0 1/14 1 0 0 0/12 0 0 0
Arthralgia 0/15 0 0 0 0/14 0 0 0 0/12 0 0 0
Leukopenia 1/15 1 0 0 1/14 1 0 0 0/12 0 0 0
Neutropenia 0/15 0 0 0 0/14 0 0 0 0/12 0 0 0
Anemia 0/15 0 0 0 1/14 1 0 0 1/12 1 0 0
Thrombocytopenia 0/15 0 0 0 0/14 0 0 0 0/12 0 0 0
Elevated ALT 1/15 1 0 0 2/14 2 0 0 0/12 0 0 0
160 mg MSP142-C1/AlhydrogelH+CPG 7909
Fever 1/15 1 0 0 3/13 3 0 0 1/12 0 1 0
Headache 5/15 4 1 0 3/13 3 0 0 4/12 4 0 0
Nausea 5/15 5 0 0 1/13 1 0 0 2/12 2 0 0
Malaise 3/15 2 1 0 4/13 2 2 0 1/12 0 1 0
Myalgia 2/15 1 1 0 1/13 0 1 0 0/12 0 0 0
Arthralgia 2/15 1 1 0 0/13 0 0 0 0/12 0 0 0
Leukopenia 1/15 1 0 0 1/13 1 0 0 1/12 1 0 0
Neutropenia 2/15 2 0 0 2/13 2 0 0 0/12 0 0 0
Anemia 0/15 0 0 0 0/13 0 0 0 1/12 1 0 0
Thrombocytopenia 0/15 0 0 0 1/13 0 1 0 1/12 0 1 0
Elevated ALT 1/15 1 0 0 0/13 0 0 0 0/12 0 0 0
doi:10.1371/journal.pone.0008787.t002
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enhancement greater at Day 42 (after the second immunization),
and for the 40 mg dose group (Table 3, all p values,0.0001). The
greatest enhancement was seen at Day 42 in the low (40 mg) dose
group, where a 49.4 fold increase was seen when CPG was
added (95% CI 24.2–103.8). Antibody responses were not
significantly higher in the 160 mg dose groups when compared
to the corresponding low dose group with or without CPG,
although there was a trend towards a higher response in the
160 mg without CPG group compared to the 40 mg without CPG
group at day 70 (2.4 fold increase, 95% CI 0.9, 4.4, p=0.07).
Responses over time are shown in Figure 3. Antibody responses
in the groups receiving CPG peaked after second vaccination,
while those without CPG peaked after third vaccination. Antibody
levels declined at similar rates in both dose groups, but remained
significantly higher at Day 238 in the groups receiving CPG.
In vitro growth-inhibitory activity was assessed with individual
IgGs from Day 0 and 70 sera using 3D7 parasites. While the
average % inhibition of Day 0 IgGs was 1% for 3D7 parasites
(ranging from 28 to 12%), Day 70 IgGs showed an average of 3%
(ranging from 22 to 10%) in the non-CPG groups and 14% (3 to
32%) in the CPG groups. There was a small, but significant,
increase in growth-inhibition activity in both non-CPG (Wilcoxon
signed rank test, p=0.0007) and CPG (p,0.0001) groups on Day
70 compared to Day 0. The Day 70 data are shown in Figure 4.
Growth-inhibitory activity was correlated with ELISA antibody
levels (Spearman correlation 0.66, 95% CI [0.46,0.79], p,0.0001).
Groups with CPG added had significantly higher GIA at Day 70
than the groups without CPG added (p,0.0001). GIA results using
FVO parasites were similar (data not shown).
Figure 2. Geometric means and 95% confidence intervals of
antibody in each group, as measured by ELISA and calculated
from the arithmetic mean of anti-MSP142-FVO and anti-
MSP142-3D7 ELISA results.
doi:10.1371/journal.pone.0008787.g002
Figure 3. Geometric mean of average of FVO and 3D7 anti-
MSP142 (ug/mL) over time. Includes only subjects with samples at all
time points (40 ug: n=12, 40 ug+CPG: n=12, 160 ug: n=10,
160 ug+CPG: n=8).
doi:10.1371/journal.pone.0008787.g003
Table 3. Fold increase in antibody responses induced by
vaccine with CPG 7909 compared to vaccine without CPG.
Dose Group and
Study Day
Fold difference in FVO/3D7 average antibody
response (95% Confidence Interval)
40 mg Day 42 49.4 (24.2, 103.8)
40 mg Day 70 8.1 (4.6, 13.6)
160 mg Day 42 20.7 (5.3, 60.4)
160 mg Day 70 4.81 (2.7, 12.4)
p,0.0001 for all tests.
doi:10.1371/journal.pone.0008787.t003
Figure 4. In vitro growth inhibition levels plotted against anti-
MSP142-3D7 antibody for 3D7 homologous parasites.
doi:10.1371/journal.pone.0008787.g004
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Both vaccines investigated in this study were well tolerated,
although local adverse events were more frequent and severe when
CPG 7909 was added and more severe when higher doses were
given. Neutropenia and malaise was more frequent in the CPG
groups. A previous study, in which a blood stage malaria vaccine
(AMA1-C1/Alhydrogel) was given to malaria naı ¨ve adults with
and without CPG 7909, showed an increase in local adverse events
and greater severity of local and systemic events with CPG, and
several volunteers were withdrawn due to adverse events [11].
However, a subsequent Phase 1 study in malaria naı ¨ve adults
showed a more favorable adverse event profile, and in Malian
adults minimal local reactogenicity and no related systemic
reactogenicity was seen [12,19]. In this study only one Grade 3
adverse event related to vaccination occurred (severe erythema),
and no volunteers were withdrawn due to adverse events.
Transient neutropenia occurred in the groups receiving CPG,
typically 3 days after vaccination with a return to baseline levels by
Day 7. Transient neutropenia has been observed in previous
studies of CPG 7909 administration and is believed to be due to
immune stimulation and white blood cell sequestration [12,20]. As
in previous studies, no clinical events occurred related to this
neutropenia and its relevance as a safety signal in this population is
doubtful.
Autoimmune disease is a theoretical concern with administra-
tion of CPG adjuvants. This concern has been heightened since
the occurrence of Wegeners Granulomatosis (an autoimmune
vasculitis affecting the lungs and kidneys) in a subject who received
a recombinant hepatitis B vaccine adjuvanted with ISS, an
oligonucleotide similar to CPG 7909 [21]. However, the causality
of a single occurrence in an early phase clinical trial is difficult to
assess, and vasculitis has also been previously reported with
licensed hepatitis B vaccines [22]. In this study no volunteers
developed laboratory markers of autoimmune disease, despite the
pre-existence of low-positive ANA in some volunteers, and no
clinical autoimmune events occurred. To date, including this
study, a total of 111 volunteers have received malaria antigens
adjuvanted with Alhydrogel and CPG 7909 [11,12,19]. While this
number is far too small to evaluate the risk of autoimmune disease
or other rare adverse events, the marked enhancement of antibody
responses with CPG must also be considered when weighing
potential risk and benefit, particularly for a vaccine intended to
prevent morbidity and mortality due to P. falciparum malaria. The
safety profile in the target population, malaria exposed children, is
as yet unknown.
Antibody is thought to be the primary mechanism of protection
against blood stages of malaria [4,5]. A previous study of AMA1-
C1/Alhydrogel with and without CPG 7909 showed up to 14-fold
enhancement of antibody responses when CPG was added [11]. In
this study the addition of CPG also markedly enhanced antibody
responses, with a 49.4 fold enhancement seen after second
vaccination with the 40 mg dose compared to the group not
receiving CPG. Also as in the previous study with AMA1-C1/
Alhydrogel, responses in the groups receiving CPG peaked after
the second vaccination, with no additional increase after the third
vaccination, and responses were similar in the high and low dose
groups when CPG was added. Thus CPG causes a dose sparing
effect, where responses after two doses with 40 mg antigen are
higher than responses after three doses with 160 mg without CPG,
and are similar to two doses with 160 mg antigen with CPG. This
dose sparing effect is particularly important in a strategy where
multiple antigens are combined, as may be required for an
effective blood stage malaria vaccine. Faster induction of antibody
responses is also an advantage, and has been seen when CPG
is added to hepatitis B vaccine [23]. Significant enhancement of
antigen specific memory B cell responses was seen after vac-
cination with malaria antigens with CPG, consistent with the
marked enhancement in antibody responses [24].
While no assays have been validated as surrogates of protection
for malaria vaccines, in vitro GIA has been utilized to measure the
biologic activity of antibodies elicited in clinical trials of blood
stage antigens [25–27]. In vitro growth inhibition of up to 96% has
been demonstrated with AMA1 vaccines [11,12,28]. Despite the
high levels of antibody induced here, comparable to those induced
when CPG was added to AMA1-C1/Alhydrogel [11,12], the
maximum level of growth inhibition induced in any volunteer was
only 32%. A previous study has shown that more anti-MSP142
antibody is required to reach the same level of inhibition in GIA
compared to anti-AMA1 antibody [16], thus although higher
antibody (and correspondingly higher GIA) was induced with the
addition of CPG, a level of inhibition likely to be biologically
significant was not achieved in any volunteer. A recent study
suggested that Fc receptor-mediated protection is important in
MSP1-induced immunity [29]. This protective mechanism cannot
be measured by GIA. Therefore, in the case of MSP142-based
vaccines investigators may need to consider other assay(s) to
evaluate the biologic function of the induced antibody.
A Phase 2b study in Kenyan children of a monovalent MSP142
vaccine adjuvanted with AS02 failed to show protection against
clinical malaria [9]. Geometric mean antibody levels induced by
vaccination in that population were ,23 mg/mL, less than those
induced in malaria naı ¨ve adults in this study. Strain-specific effects
have been demonstrated in an Aotus model when animals received
an MSP142 vaccine with complete Freund’s adjuvant [8], and may
also have played a part in the lack of benefit demonstrated in
Kenyan children. The same Aotus study showed no protection with
an MSP142 vaccine adjuvanted with AS02, but showed some
protection with the same vaccine in a water-in-oil adjuvant (ISA
720), and the authors speculate that a Th1-biased adjuvant such as
CPG could be added to induce additional protection.
It seems likely that a recombinant blood stage malaria vaccine
will require multiple proteins, both to overcome diversity of the
allelic antigens expressed by the parasites and to overcome
diversity of responses in the target population. Which combination
of antigens is most likely to be protective is as yet unknown, with
the epidemiologic evidence conflicting [30–33]. Clinical develop-
ment of blood stage vaccines is largely empiric, since correlates of
protection are unknown. Vaccines which have been judged to be
safe and adequately immunogenic have gone forward to Phase 2b
trials in African children, but given the lack of protection
demonstrated to date this approach may no longer be feasible.
A human blood stage challenge using parasite-infected erythro-
cytes is under development and may prove useful in allowing down
selection of blood stage vaccine candidates prior to large field trials
[34,35]. While further clinical development of MSP142/Alhydro-
gel + CPG 7909 as a separate candidate vaccine is not currently
anticipated, the good safety profile, high antibody responses, and
biologic function of the induced antibody demonstrated in this trial
provide a rationale for the inclusion of MSP142/Alhydrogel +
CPG 7909 as part of a combination blood stage vaccine, which is
currently in early phase clinical development (ClinicalTrials.gov
Identifier: NCT00889616). Demonstration of homologous protec-
tion in either a human challenge or non-human primate model
(using adjuvants suitable for use in humans) would provide support
for continued clinical development, although such models are as
yet unvalidated with respect to their ability to predict protection in
the target population. Demonstration of likely benefit may be of
MSP142-C1/Alhydrogel6CPG 7909
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profile, such as CPG 7909, are part of the clinical formulation.
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